Comparative Pharmacology
Head-to-head clinical analysis: PLEGISOL IN PLASTIC CONTAINER versus SUTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLEGISOL IN PLASTIC CONTAINER versus SUTAB.
PLEGISOL IN PLASTIC CONTAINER vs SUTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PLEGISOL is an extracellular-type crystalloid cardioplegic solution used for myocardial protection during cardiac surgery. Its mechanism involves inducing rapid cardiac arrest by high potassium concentration (depolarizing arrest), reducing myocardial oxygen demand, and providing buffering capacity via tromethamine to maintain pH. The solution also contains magnesium to stabilize membranes and mannitol as an osmotic agent to reduce edema.
SUTAB is a combination tablet consisting of sodium sulfate, magnesium sulfate, and potassium chloride. It acts as an osmotic laxative by drawing water into the bowel lumen through the osmotic effect of sulfate ions, inducing colonic evacuation. Additionally, magnesium ions enhance this effect by attracting water via osmotic pressure and stimulating the release of cholecystokinin, which promotes peristalsis.
Administered as an intraperitoneal infusion for organ preservation. Typical adult dose: 2.5-3.0 liters for kidney, 2.5-3.0 liters for liver, 3.0-4.0 liters for pancreas, single dose prior to procurement.
24 tablets administered as 4 tablets every 15 minutes, total dose of 17.5 g sodium sulfate, 3.13 g magnesium sulfate, and 1.64 g potassium sulfate, orally, with water, the evening before colonoscopy.
None Documented
None Documented
Not applicable; Plegisol is not a systemically active drug. Its cardioplegic effect is immediate upon perfusion into coronary arteries and dissipates upon reperfusion. The solution's components have endogenous half-lives (e.g., potassium: 1-1.5 h in plasma), but this is not clinically relevant for the product.
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 20-40 hours in end-stage renal disease.
Plegisol is an extracellular cardioplegic solution; its components (electrolytes and calcium) are not metabolized. Elimination of infused volume occurs primarily via renal excretion (approx. 95%) as unchanged water and electrolytes; minor biliary/fecal elimination (<5%) accounts for negligible electrolyte loss.
Primarily renal excretion (65-75% unchanged) with minor biliary/fecal elimination (<10%). Total body clearance approximates renal blood flow.
Category C
Category C
Osmotic Laxative
Osmotic Laxative